• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估德国心血管高危和极高危患者中他汀不耐受的患病率及特征(2017年至2020年)

Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020).

作者信息

Parhofer Klaus G, Anastassopoulou Anastassia, Calver Henry, Becker Christian, Rathore Anirudh S, Dave Raj, Zamfir Cosmin

机构信息

Ludwig Maximilians University, Medical Clinic IV, Großhadern, 81377 Munich, Germany.

Daiichi Sankyo Europe GmbH, Zielstattstraße 48, 81379 Munich, Germany.

出版信息

J Clin Med. 2023 Jan 16;12(2):705. doi: 10.3390/jcm12020705.

DOI:10.3390/jcm12020705
PMID:36675634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9864390/
Abstract

Statin intolerance (SI) (partial and absolute) could lead to suboptimal lipid management. The lack of a widely accepted definition of SI results into poor understanding of patient profiles and characteristics. This study aims to estimate SI and better understand patient characteristics, as reflected in clinical practice in Germany using supervised machine learning (ML) techniques. This retrospective cohort study utilized patient records from an outpatient setting in Germany in the IQVIA™ Disease Analyzer. Patients with a high cardiovascular risk, atherosclerotic cardiovascular disease, or hypercholesterolemia, and those on lipid-lowering therapies between 2017 and 2020 were included, and categorized as having “absolute” or “partial” SI. ML techniques were applied to calibrate prevalence estimates, derived from different rules and levels of confidence (high and low). The study included 292,603 patients, 6.4% and 2.8% had with high confidence absolute and partial SI, respectively. After deploying ML, SI prevalence increased approximately by 27% and 57% (p < 0.00001) in absolute and partial SI, respectively, eliciting a maximum estimate of 12.5% SI with high confidence. The use of advanced analytics to provide a complementary perspective to current prevalence estimates may inform the identification, optimal treatment, and pragmatic, patient-centered management of SI in Germany.

摘要

他汀类药物不耐受(SI)(部分和绝对不耐受)可能导致脂质管理不理想。由于缺乏对SI的广泛接受的定义,导致对患者概况和特征的了解不足。本研究旨在估计SI,并更好地了解患者特征,这在德国的临床实践中通过监督机器学习(ML)技术得以体现。这项回顾性队列研究利用了德国门诊环境中IQVIA™疾病分析仪的患者记录。纳入了具有高心血管风险、动脉粥样硬化性心血管疾病或高胆固醇血症的患者,以及2017年至2020年间接受降脂治疗的患者,并将其分类为具有“绝对”或“部分”SI。应用ML技术校准从不同规则和置信水平(高和低)得出的患病率估计值。该研究纳入了292,603名患者,分别有6.4%和2.8%的患者被高度置信为绝对和部分SI。在应用ML后,绝对和部分SI的SI患病率分别增加了约27%和57%(p < 0.00001),得出高度置信下SI的最高估计值为12.5%。使用先进的分析方法为当前的患病率估计提供补充视角,可能有助于德国SI的识别、优化治疗以及务实的、以患者为中心的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/8f3e7f29aa8d/jcm-12-00705-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/cc5f0ba7c169/jcm-12-00705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/8411f2332e50/jcm-12-00705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/2b517081c3ce/jcm-12-00705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/8f3e7f29aa8d/jcm-12-00705-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/cc5f0ba7c169/jcm-12-00705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/8411f2332e50/jcm-12-00705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/2b517081c3ce/jcm-12-00705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9707/9864390/8f3e7f29aa8d/jcm-12-00705-g004.jpg

相似文献

1
Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020).评估德国心血管高危和极高危患者中他汀不耐受的患病率及特征(2017年至2020年)
J Clin Med. 2023 Jan 16;12(2):705. doi: 10.3390/jcm12020705.
2
Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia.患有治疗抵抗性高胆固醇血症的高危心血管疾病患者的患病率。
Cardiovasc Endocrinol. 2017 Jun;6(2):81-85. doi: 10.1097/XCE.0000000000000098. Epub 2016 Oct 14.
3
Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study.在大型综合医疗机构中,新诊断为动脉粥样硬化性心血管疾病患者他汀类药物不耐受的预测因素:IMPRES 研究。
J Cardiovasc Pharmacol. 2020 May;75(5):426-431. doi: 10.1097/FJC.0000000000000808.
4
Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.降脂治疗在动脉粥样硬化性心血管疾病或糖尿病患者中的应用模式:韩国的一项基于人群的研究。
Clin Ther. 2018 Jun;40(6):940-951.e7. doi: 10.1016/j.clinthera.2018.04.007. Epub 2018 May 5.
5
Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management.他汀类药物不耐受患者的未满足需求:临床特征与管理。
Cardiovasc Drugs Ther. 2018 Feb;32(1):29-36. doi: 10.1007/s10557-018-6775-0.
6
Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan.台湾临床动脉粥样硬化性心血管疾病(ASCVD)或糖尿病(DM)他汀类药物使用者中降脂治疗模式及可能的他汀类药物不耐受情况
J Eval Clin Pract. 2020 Aug;26(4):1171-1180. doi: 10.1111/jep.13286. Epub 2019 Oct 23.
7
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).阿利西尤单抗治疗动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症患者难治性高胆固醇血症的优化治疗(OPTIMIZE)。
Front Cardiovasc Med. 2022 Jul 15;9:953040. doi: 10.3389/fcvm.2022.953040. eCollection 2022.
8
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.他汀类药物不耐受对满足动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇目标的依折麦布和/或前蛋白转化酶枯草溶菌素 9 抑制剂需求的影响模拟。
Am J Cardiol. 2019 Apr 15;123(8):1202-1207. doi: 10.1016/j.amjcard.2019.01.028. Epub 2019 Jan 25.
9
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.在管理式医疗环境中,以低高密度脂蛋白胆固醇为靶点降低残余心血管风险。
J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.
10
Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database.美国行政数据库中识别他汀类药物不耐受算法的开发与验证
Value Health. 2016 Sep-Oct;19(6):852-860. doi: 10.1016/j.jval.2016.03.1858. Epub 2016 May 11.

引用本文的文献

1
Determining cost-saving risk thresholds for statin use.确定他汀类药物使用的成本节约风险阈值。
PLoS One. 2025 Mar 13;20(3):e0318454. doi: 10.1371/journal.pone.0318454. eCollection 2025.
2
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study.他汀类药物不耐受的心血管高危和极高危患者的 LDL 胆固醇目标达标情况:一项模拟研究。
Sci Rep. 2024 Jan 4;14(1):474. doi: 10.1038/s41598-023-50847-1.

本文引用的文献

1
Individualized therapy in statin intolerance: the key to success.他汀不耐受的个体化治疗:成功的关键。
Eur Heart J. 2023 Feb 14;44(7):544-546. doi: 10.1093/eurheartj/ehac556.
2
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).逐步诊断和管理他汀类药物相关肌肉症状患者的安慰剂/反安慰剂效应:国际脂质专家组(ILEP)的立场文件。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.
3
Prevalence of statin intolerance: a meta-analysis.
他汀类药物不耐受的流行率:一项荟萃分析。
Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.
4
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.他汀类药物、安慰剂和无治疗交叉试验中的副作用模式。
J Am Coll Cardiol. 2021 Sep 21;78(12):1210-1222. doi: 10.1016/j.jacc.2021.07.022.
5
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort.贝匹地酸和 PCSK9 抑制剂的目标人群和治疗费用:当代 CAD 队列中的模拟研究。
Clin Ther. 2021 Sep;43(9):1583-1600. doi: 10.1016/j.clinthera.2021.07.019. Epub 2021 Aug 27.
6
Impact of the COVID-19 Pandemic on Consultations and Diagnoses in Gastroenterology Practices in Germany.新冠疫情对德国胃肠病学实践中会诊与诊断的影响
Front Med (Lausanne). 2021 May 31;8:684032. doi: 10.3389/fmed.2021.684032. eCollection 2021.
7
Statin intolerance: new data and further options for treatment.他汀类药物不耐受:新数据和治疗的新选择。
Curr Opin Cardiol. 2021 Jul 1;36(4):487-493. doi: 10.1097/HCO.0000000000000874.
8
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.欧盟范围内二级和初级保健中使用调脂治疗的横断面观察性研究:DA VINCI 研究。
Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289. doi: 10.1093/eurjpc/zwaa047.
9
Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians.使用他汀类药物的障碍与促进因素:一项针对患者和家庭医生的定性研究
CJC Open. 2020 Jul 4;2(6):530-538. doi: 10.1016/j.cjco.2020.07.002. eCollection 2020 Nov.
10
Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada.提高高心血管疾病风险患者降脂药物起始率的策略:加拿大阿尔伯塔省促进接力干预措施中患者和全科医生观点的定性描述性探索。
BMJ Open. 2020 Nov 24;10(11):e038469. doi: 10.1136/bmjopen-2020-038469.